# lung adenocarcinoma (LUAD) - gemini-3.6-flash

- Benchmark system: raw
- Repeat: 7
- Task type: PROGNOSIS
- Tissue / sample source: lung adenocarcinoma tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: a2c9355177479f23c6c81afe1b39ba697ac131cc344bb83120b98e2c6bbfee49
- Response HTTP status: 200
- Prompt tokens: 4353
- Completion tokens: 12070
- Reasoning tokens: 
- Total tokens: 16423
- API requests reported: 
- Elapsed seconds: 83.355
- Final benchmark system: raw; file rank 5/5; original repeat 7; model vendor: Google Gemini

---
### 1. Overall Biological Interpretation

The prognostic transcriptomic dataset from lung adenocarcinoma (LUAD) primary tumor tissue reveals a distinct dichotomy between **methodological artifacts** and **authentic biological programs**:

1. **Methodological & Numerical Separation Signals:** A substantial cohort of features exhibits extreme hazard ratios ($\text{HR} > 10^9$ or $\text{HR} \approx 0$) accompanied by $P=0$ and $\text{FDR}=0$ (e.g., $RBMY1F$, $TTTY4C$, $Y\_RNA$, $RNU6-78P$, $TCP10L3$). Rather than representing true biological super-drivers, these extreme values represent a bioinformatic artifact known as **complete or quasi-complete separation** in Cox proportional hazards regression. This occurs when transcripts have near-zero baseline variance, sparse non-zero expression in very few samples, or are strictly sex-linked (e.g., Y-chromosome transcripts evaluated in mixed-sex cohorts without sex adjustment).
2. **Robust Biological Risk Signals:** Among transcripts with realistic, unseparated effect sizes ($1.2 < \text{HR} < 1.5$), three primary biological themes drive poor overall survival (OS):
   * **Wnt/Notch-Associated Transcriptional Corepression and Differentiation Control:** Coordinated hazard elevation in canonical pathways regulating tumor cell stemness and transcriptional repression ($DKK1$, $TLE1$, $PITX3$).
   * **Cytoskeletal Plasticity, Glycosylation, and Cell Motility:** Elevated expression of structural cytoskeletal genes ($KRT6A$), actin GTPases ($RHOF$), cell surface glycosyltransferases ($FUT4$), and endocytic receptors ($LDLRAD3$), indicating a cellular phenotype primed for invasive and metastatic behavior.
   * **Oncogenic vs. Tumor-Suppressive Non-Coding RNA Networks:** A distinct regulatory layer composed of risk-associated long non-coding RNAs ($LINC00707$, $ITGB1\text{-}DT$, $LINC01312$) alongside protective non-coding elements ($CRNDE$, $\text{HR} = 0.716$).

---

### 2. Core Biological Programs

```
                  ┌─────────────────────────────────────────────────────────┐
                  │              LUAD Prognostic Landscape                  │
                  └────────────────────────────┬────────────────────────────┘
                                               │
         ┌─────────────────────────────────────┼─────────────────────────────────────┐
         │                                     │                                     │
┌────────┴────────┐                   ┌────────┴────────┐                   ┌────────┴────────┐
│  Program 1:     │                   │  Program 2:     │                   │  Program 4:     │
│  Wnt/Notch      │                   │  Motility &     │                   │  Non-Coding RNA │
│  Repression     │                   │  Extracellular  │                   │  Networks       │
│                 │                   │  Remodeling     │                   │                 │
│ • DKK1          │                   │ • KRT6A         │                   │ • LINC00707     │
│ • TLE1          │                   │ • FUT4          │                   │ • ITGB1-DT      │
│ • PITX3         │                   │ • RHOF          │                   │ • CRNDE         │
│                 │                   │ • LDLRAD3       │                   │   (protective)  │
└─────────────────┘                   └─────────────────┘                   └─────────────────┘
```

#### Program 1: Wnt / β-Catenin Pathway Modulation & Transcriptional Corepression
* **Direction / Prognostic Association:** Risk-associated ($\text{HR} > 1$, shorter OS).
* **Major Supporting Genes:** $DKK1$ ($\text{HR} = 1.475, P = 4.27 \times 10^{-10}$), $TLE1$ ($\text{HR} = 1.484, P = 3.20 \times 10^{-8}$), $PITX3$ ($\text{HR} = 1.429, P = 4.14 \times 10^{-14}$).
* **Standardized Pathway:** Reactome: *Signaling by WNT* (R-HSA-195721); KEGG: *Wnt signaling pathway* (hsa04310).
* **Biological Explanation:** $DKK1$ is a secreted Wnt pathway modulator whose overexpression in advanced LUAD often correlates with cancer stem cell maintenance, immunosuppressive microenvironment remodelling, and aggressive tumor growth. $TLE1$ functions as a Groucho-family transcriptional corepressor that interacts with TCF/LEF and Notch downstream effectors to enforce un-differentiated, stem-like cellular phenotypes. $PITX3$ is a homeobox transcription factor controlling developmental lineage specification. Together, elevated expression of these transcripts reflects a high-risk transcriptional state enriched for stemness and dysregulated Wnt/Notch pathway signaling.
* **Evidence Strength & Limitations:** High statistical confidence ($P < 10^{-7}$, realistic FDRs). A limitation is that bulk RNA expression cannot distinguish whether $DKK1$ originates from neoplastic epithelial cells or stromal/microenvironmental compartments.

#### Program 2: Cytoskeletal Plasticity, Glycosylation, and Cell Motility
* **Direction / Prognostic Association:** Risk-associated ($\text{HR} > 1$, shorter OS).
* **Major Supporting Genes:** $KRT6A$ ($\text{HR} = 1.390, P = 4.22 \times 10^{-7}$), $FUT4$ ($\text{HR} = 1.403, P = 4.55 \times 10^{-7}$), $RHOF$ ($\text{HR} = 1.403, P = 6.31 \times 10^{-7}$), $LDLRAD3$ ($\text{HR} = 1.420, P = 3.34 \times 10^{-7}$).
* **Standardized Pathway:** GO:0007155 (*Cell Adhesion*); Reactome: *Rho GTPase cycle* (R-HSA-194315).
* **Biological Explanation:** This program captures structural and enzymatic machinery driving tumor cell invasion and metastasis. $KRT6A$ (Cytokeratin 6A) marks squamous-like lineage plasticity, epithelial-mesenchymal transition (EMT), and invasion in lung adenocarcinomas. $FUT4$ (Fucosyltransferase 4) synthesizes fucosylated cell-surface glycan antigens (e.g., Lewis X/Y) that mediate selectin binding, extravasation, and cell adhesion. $RHOF$ (Rif) is an atypical Rho GTPase regulating filopodia formation and actin dynamics, while $LDLRAD3$ plays roles in endocytic receptor recycling. Convergence across these genes reflects an active metastatic cell motility program.
* **Evidence Strength & Limitations:** Consistent statistical effect sizes ($\text{HR} \approx 1.39–1.42$). Limitations include lack of direct single-cell localization to confirm whether these structural changes occur in primary tumor cells or reactive tumor stroma.

#### Program 3: G-Protein Signaling and Membrane Transport Regulation
* **Direction / Prognostic Association:** Risk-associated ($\text{HR} > 1$, shorter OS).
* **Major Supporting Genes:** $RGS20$ ($\text{HR} = 1.352, P = 9.55 \times 10^{-7}$), $RHCG$ ($\text{HR} = 1.290, P = 7.64 \times 10^{-7}$), $VAX1$ ($\text{HR} = 1.335, P = 1.16 \times 10^{-8}$).
* **Standardized Pathway:** KEGG: *GPCR downstream signaling* (hsa04024); GO:0006810 (*Transport*).
* **Biological Explanation:** $RGS20$ (Regulator of G-protein Signaling 20) attenuates specific $\text{G}\alpha_{\text{i/o}}$ signaling cascades, enhancing cell survival, chemoresistance, and migratory capacity in solid tumors. $RHCG$ is an ammonium transmembrane transporter involved in handling metabolic waste and controlling intracellular/extracellular microenvironmental pH. $VAX1$ is a transcription factor involved in tissue patterning. Elevated expression of these genes indicates adaptation to microenvironmental stress and active signal transduction.
* **Evidence Strength & Limitations:** Moderate statistical evidence ($P \approx 10^{-6}–10^{-8}$). The functional connectivity between ammonium transport ($RHCG$) and RGS signaling ($RGS20$) is co-expression-based rather than direct physical interaction.

#### Program 4: Non-Coding RNA Regulatory Network
* **Direction / Prognostic Association:** Bi-directional (predominantly Risk-associated; select Protective lncRNAs).
* **Major Supporting Genes:** Risk: $LINC00707$ ($\text{HR} = 1.318$), $ITGB1\text{-}DT$ ($\text{HR} = 1.302$), $LINC01312$ ($\text{HR} = 1.364$), $LINC02178$ ($\text{HR} = 1.297$). Protective: $CRNDE$ ($\text{HR} = 0.716, P = 1.41 \times 10^{-7}$).
* **Standardized Pathway:** Reactome: *RNA Pol II transcription of non-coding RNA* (R-HSA-425561).
* **Biological Explanation:** Non-coding RNAs act as epigenetic and post-transcriptional regulators in LUAD. $LINC00707$ and $ITGB1\text{-}DT$ promote oncogenesis by acting as microRNA sponges or modulating adjacent gene expression (e.g., $ITGB1$ integrin signaling). Conversely, $CRNDE$ displays a protective hazard ratio ($\text{HR} = 0.716$), suggesting cell-type specific or context-dependent tumor suppressor activity in this specific LUAD cohort.
* **Evidence Strength & Limitations:** Statistically robust, but non-coding transcripts generally lack complete functional annotation, making exact mechanistic assignments exploratory.

#### Program 5: Technical Separation & Sex-Linked Artifact Cluster
* **Direction / Prognostic Association:** Computational extremes ($\text{HR} > 10^9$ or $\text{HR} \approx 0, P=0, \text{FDR}=0$).
* **Major Supporting Genes:** $RBMY1F$, $TTTY4C$, $USP9YP3$, $CDY10P$, $Y\_RNA$, $RNU6\text{-}78P$, $TCP10L3$.
* **Standardized Pathway:** Not applicable (Methodological artifact).
* **Biological Explanation:** Extreme HR values arise from statistical separation in univariable Cox models. Y-chromosome loci ($TTTY4C$, $RBMY1F$, $USP9YP3$) are strictly expressed in male samples; if events/deaths are disproportionately distributed between male and female subsets in the dataset, univariable Cox regression models yield infinite or near-infinite hazard ratios due to zero variance in the female subset. Similarly, low-abundance pseudogenes or snRNAs with zero counts across most patients cause complete separation.
* **Evidence Strength & Limitations:** High diagnostic certainty as a statistical artifact. These entries must be filtered prior to downstream clinical model construction.

---

### 3. Key Genes and Interaction Modules

```
┌────────────────────────────────────────────────────────────────────────────────────────┐
│                        Key Genes & Interaction Architecture                            │
├──────────────────────────┬─────────────┬─────────────────────────┬─────────────────────┤
│ Gene Symbol              │ Association │ Core Biological Program │ Interaction Type    │
├──────────────────────────┼─────────────┼─────────────────────────┼─────────────────────┤
│ DKK1                     │ Risk        │ Wnt / Stemness          │ Pathway co-mem.     │
│ TLE1                     │ Risk        │ Wnt / Corepression      │ Pathway co-mem.     │
│ KRT6A                    │ Risk        │ Cytoskeleton / EMT      │ Co-expression       │
│ FUT4                     │ Risk        │ Glycosylation           │ Putative / Indirect │
│ RHOF                     │ Risk        │ Actin Remodeling        │ Pathway co-mem.     │
│ PITX3                    │ Risk        │ Differentiation TF      │ Putative / Indirect │
│ RGS20                    │ Risk        │ GPCR Signaling          │ Putative / Indirect │
│ LINC00707                │ Risk        │ Non-Coding RNA          │ Co-expression       │
│ CRNDE                    │ Protective  │ Non-Coding RNA          │ Co-expression       │
│ TTTY4C / RBMY1F (Module) │ Extreme (Y) │ Technical Artifact      │ Genomic Linkage     │
└──────────────────────────┴─────────────┴─────────────────────────┴─────────────────────┘
```

1. **$DKK1$ ($\text{HR} = 1.475, P = 4.27 \times 10^{-10}$)**
   * **Role:** Secreted antagonist of canonical Wnt/$\beta$-catenin signaling; promotes stemness, invasive properties, and immune evasion in lung cancer.
   * **Proposed Relationship:** *Pathway co-membership* with $TLE1$ in modulating Wnt pathway transcription.

2. **$TLE1$ ($\text{HR} = 1.484, P = 3.20 \times 10^{-8}$)**
   * **Role:** Transcriptional corepressor binding TCF/LEF and Hes factors to repress gene expression linked to terminal epithelial differentiation.
   * **Proposed Relationship:** *Pathway co-membership* with $DKK1$; *indirect/putative relationship* with $PITX3$ in transcriptional control.

3. **$KRT6A$ ($\text{HR} = 1.390, P = 4.22 \times 10^{-7}$)**
   * **Role:** Intermediate filament protein involved in cytoskeletal integrity, cell motility, and squamous lineage plasticity in aggressive LUAD variants.
   * **Proposed Relationship:** *Co-expression* with $RHOF$ and $FUT4$ as part of an invasive cell motility and matrix interaction module.

4. **$FUT4$ ($\text{HR} = 1.403, P = 4.55 \times 10^{-7}$)**
   * **Role:** Alpha-(1,3)-fucosyltransferase catalyzing the synthesis of tumor-associated carbohydrate antigens (e.g., Lewis X), facilitating cell-cell and cell-matrix interactions.
   * **Proposed Relationship:** *Indirect or putative relationship* with $ITGB1\text{-}DT$ and $KRT6A$ in cell adhesion dynamics.

5. **$RHOF$ ($\text{HR} = 1.403, P = 6.31 \times 10^{-7}$)**
   * **Role:** Small GTPase of the Rho family regulating filopodia dynamics and actin cytoskeletal reorganization.
   * **Proposed Relationship:** *Pathway co-membership* with cell adhesion machinery ($KRT6A$, $LDLRAD3$) in cell migration (GO:0007155).

6. **$PITX3$ ($\text{HR} = 1.429, P = 4.14 \times 10^{-14}$)**
   * **Role:** Homeobox transcription factor involved in developmental lineage control and cell fate specification.
   * **Proposed Relationship:** *Indirect or putative relationship* with $TLE1$ in modulating differentiation programs.

7. **$RGS20$ ($\text{HR} = 1.352, P = 9.55 \times 10^{-7}$)**
   * **Role:** Regulator of G-protein signaling that negatively regulates $\text{G}\alpha_{\text{i/o}}$ protein subunits, driving survival and migration.
   * **Proposed Relationship:** *Indirect or putative relationship* with intracellular signal transduction cascades.

8. **$LINC00707$ ($\text{HR} = 1.318, P = 7.57 \times 10^{-7}$)**
   * **Role:** Oncogenic long non-coding RNA that acts as a competitive endogenous RNA (ceRNA) to sponge tumor-suppressive miRNAs.
   * **Proposed Relationship:** *Co-expression* with other non-coding risk transcripts ($ITGB1\text{-}DT$, $LINC01312$).

9. **$CRNDE$ ($\text{HR} = 0.716, P = 1.41 \times 10^{-7}$)**
   * **Role:** Protective long non-coding RNA in this dataset, potential suppressor of aggressive growth or regulator of chromatin architecture in specific LUAD contexts.
   * **Proposed Relationship:** *Co-expression / Regulatory contrast* with risk-associated lncRNAs.

10. **$TTTY4C$ / $RBMY1F$ (Y-Linked Artifact Cluster, $\text{HR} > 10^{21}$)**
    * **Role:** Y-chromosome-specific genes acting as markers of patient sex rather than direct cancer driver genes.
    * **Proposed Relationship:** *Genomic linkage* (co-localization on Chromosome Y) causing co-separation in univariable Cox models.

---

### 4. Validation Priorities

```
┌────────────────────────────────────────────────────────────────────────────────────────┐
│                                 Validation Roadmap                                     │
├───────────────────────┬───────────────────────────────────┬────────────────────────────┤
│ Priority Level        │ Target / Hypothesis               │ Category                   │
├───────────────────────┼───────────────────────────────────┼────────────────────────────┤
│ 1. High Priority      │ Sex & Count Separation Correction │ Confounding / Comp. Check  │
│ 2. High Priority      │ DKK1 / TLE1 Corepression Axis     │ Mechanistic Hypothesis     │
│ 3. Medium Priority    │ KRT6A / FUT4 Invasive Score       │ Biomarker                  │
│ 4. Medium Priority    │ LINC00707 Regulatory Network      │ Interaction Hypothesis     │
│ 5. Exploratory        │ RGS20 Signaling Inhibition        │ Therapeutic Target         │
└───────────────────────┴───────────────────────────────────┴────────────────────────────┘
```

#### Priority 1: Methodological Correction for Sex-Linked and Low-Count Separation
* **Classification:** Confounding or composition check.
* **Why It Deserves Prioritization:** Transcripts like $RBMY1F$, $TTTY4C$, and $USP9YP3$ display non-physiological hazard ratios ($\text{HR} > 10^{21}$) due to complete statistical separation. Left uncorrected, these artifacts corrupt multivariable risk scoring models.
* **Current Dataset Evidence:** Extreme hazard ratios ($\text{HR} > 10^9$) paired with $P = 0, \text{FDR} = 0$.
* **External Evidence:** Documented statistical phenomena in cancer genomics (TCGA datasets) where Y-chromosome transcripts produce infinite hazard ratios if sex is omitted from multivariable models.
* **Next Step for Validation:** Re-analyze survival using **Firth’s penalized Cox proportional hazards regression** and incorporate patient sex, age, tumor purity, and stage as mandatory covariates.
* **Status:** Established evidence (regarding the presence of statistical confounding/separation).

#### Priority 2: Mechanistic Role of Dual Wnt/Notch Repression ($DKK1$ and $TLE1$) in LUAD OS
* **Classification:** Mechanistic hypothesis.
* **Why It Deserves Prioritization:** $DKK1$ and $TLE1$ represent two highly significant risk predictors ($\text{HR} \approx 1.48, P < 10^{-7}$) operating in convergent stemness and transcriptional corepression pathways.
* **Current Dataset Evidence:** Both genes are independently associated with shortened overall survival in univariable Cox analyses.
* **External Evidence:** Literature confirms $DKK1$ secretion promotes cancer stem cell expansion and immunosuppressive macrophage infiltration in lung cancer, while $TLE1$ suppresses pro-differentiation genes.
* **Next Step for Validation:** Perform dual siRNA/shRNA knockdown of $DKK1$ and $TLE1$ in LUAD cell lines (e.g., A549, H1299), followed by Wnt reporter assays (TOPFlash) and matrigel invasion assays.
* **Status:** Supported hypothesis.

#### Priority 3: Protein-Level Biomarker Validation of an Invasive Phenotype ($KRT6A$ + $FUT4$)
* **Classification:** Biomarker.
* **Why It Deserves Prioritization:** Cytoskeletal ($KRT6A$) and glycosylation ($FUT4$) markers provide actionable targets for prognostic immunohistochemistry (IHC) assays in routine clinical pathology.
* **Current Dataset Evidence:** $KRT6A$ ($\text{HR} = 1.390$) and $FUT4$ ($\text{HR} = 1.403$) show consistent statistical significance ($P < 5 \times 10^{-7}$).
* **External Evidence:** $KRT6A$ overexpression is linked to EGFR-TKI resistance and poor outcomes in NSCLC; $FUT4$ synthesis of Lewis antigens is established in metastatic colonization.
* **Next Step for Validation:** Immunohistochemical (IHC) staining of KRT6A and FUT4 on an independent tissue microarray (TMA) cohort of LUAD patients with annotated clinical follow-up.
* **Status:** Supported hypothesis.

#### Priority 4: Regulatory Architecture of $LINC00707$ in Lung Adenocarcinoma
* **Classification:** Interaction / network hypothesis.
* **Why It Deserves Prioritization:** $LINC00707$ is one of the top non-coding risk transcripts ($\text{HR} = 1.318, P = 7.57 \times 10^{-7}$) in the current dataset.
* **Current Dataset Evidence:** Strong statistical signal for risk association in primary LUAD tissue.
* **External Evidence:** Literature suggests $LINC00707$ can act as a sponge for miR-145 and miR-370, promoting downstream expression of oncogenic TFs.
* **Next Step for Validation:** Perform RNA pull-down followed by mass spectrometry and microRNA sequencing in LUAD cell lines to map the precise interactome of $LINC00707$.
* **Status:** Exploratory hypothesis.

#### Priority 5: Therapeutic Vulnerability of $RGS20$ Signaling in Aggressive LUAD
* **Classification:** Therapeutic target.
* **Why It Deserves Prioritization:** Regulators of G-protein signaling (RGS) contain druggable pockets and mediate survival signals under hypoxic microenvironmental conditions.
* **Current Dataset Evidence:** $RGS20$ is significantly associated with poor OS ($\text{HR} = 1.352, P = 9.55 \times 10^{-7}$).
* **External Evidence:** Overexpression of $RGS20$ is associated with increased cell migration and invasive behavior in epithelial tumors.
* **Next Step for Validation:** Target $RGS20$ via shRNA or small-molecule RGS inhibitors in patient-derived 3D organoid models of LUAD to assess impacts on cell viability and motility.
* **Status:** Exploratory hypothesis.

---

### 5. Evidence Grounding

```
┌────────────────────────────────────────────────────────────────────────────────────────┐
│                              Evidence Matrix & Sources                                 │
├──────────────────────┬──────────────────────┬───────────────────┬──────────────────────┤
│ Program / Gene       │ Direct Dataset       │ Pathway / PPI     │ Literature / Clinical│
├──────────────────────┼──────────────────────┼───────────────────┼──────────────────────┤
│ Artifact Cluster     │ Extreme HRs (10^21)  │ N/A               │ Known Cox separation │
│ Wnt (DKK1/TLE1)      │ HR ~ 1.48, P < 10^-7 │ KEGG: Wnt         │ Stemness / Immunity  │
│ Motility (KRT6A/FUT4)│ HR ~ 1.40, P < 10^-6 │ GO: Cell Adhesion │ EMT / Metastasis     │
│ LncRNAs (LINC00707)  │ HR ~ 1.32, P < 10^-6 │ RNA Pol II ncRNA  │ MicroRNA sponging    │
│ CRNDE (Protective)   │ HR ~ 0.72, P < 10^-6 │ RNA Pol II ncRNA  │ Tissue-type conflict │
└──────────────────────┴──────────────────────┴───────────────────┴──────────────────────┘
```

1. **Direct Input Dataset Evidence:** The hazard ratios, $P$-values, and FDRs provided serve as the primary statistical evidence. Unseparated signals ($DKK1, TLE1, KRT6A, FUT4, RHOF, RGS20, LINC00707$) demonstrate moderate hazard ratios ($\text{HR} = 1.29–1.48$) with robust false discovery control ($\text{FDR} < 0.001$).
2. **Pathway & Ontology Evidence:** Standardized enrichment in *Reactome: Signaling by WNT* ($DKK1, TLE1$), *GO: Cell Adhesion* ($FUT4, KRT6A$), and *Reactome: Rho GTPase cycle* ($RHOF$) provides independent, pathway-level convergence. These sources are largely independent of the input dataset but draw from overlapping biological databases (e.g., MSigDB, KEGG).
3. **Protein Interaction & Regulatory Evidence:** Direct physical protein-protein interaction (PPI) databases (e.g., STRING, BioGRID) support $TLE1$ interacting with TCF/LEF factors downstream of Wnt signaling. However, no direct physical interaction is documented between $DKK1$ (secreted) and $TLE1$ (nuclear corepressor); their relationship is strictly **pathway co-membership**.
4. **Literature & Tissue-Specific Evidence vs. Conflicts:**
   * **Concordance:** Literature broadly supports $DKK1$, $KRT6A$, and $FUT4$ as markers of tumor aggressiveness and poor survival in non-small cell lung cancer (NSCLC).
   * **Conflict:** $CRNDE$ displays a protective hazard ratio ($\text{HR} = 0.716, P = 1.41 \times 10^{-7}$) in this input dataset. In contrast, extensive literature in gastrointestinal cancers (colon, gastric) characterizes $CRNDE$ as an oncogenic driver. This conflict highlights tissue-specific lncRNA wiring or transcript isoform variation between gastrointestinal carcinomas and lung adenocarcinomas.

---

### 6. Limitations and Alternative Explanations

1. **Complete Separation and Firth Bias in Cox Regression:**
   * *Limitation:* The presence of hazard ratios on the order of $10^{21}$ ($RBMY1F$, $TTTY4C$, $RNU6\text{-}78P$) confirms complete or quasi-complete separation. This occurs when a binary covariate or near-zero expression count perfectly predicts survival time, destabilizing maximum likelihood estimation in standard Cox models.
   * *Investigation:* Apply Firth’s penalized maximum likelihood estimation or exclude features with non-zero expression in $< 5\%$ of samples.

2. **Unadjusted Confounding by Patient Sex:**
   * *Limitation:* The presence of Y-chromosome genes ($TTTY4C$, $RBMY1F$, $USP9YP3$) among top risk predictors indicates that survival analyses were likely unvariable and not adjusted for sex. If male sex correlates with worse overall survival in this cohort, all Y-linked genes falsely acquire extreme hazard ratios.
   * *Investigation:* Perform multivariable Cox regression stratified by sex or include sex as an explicit covariate.

3. **Cellular Composition and Microenvironment Heterogeneity:**
   * *Limitation:* Bulk transcriptomic profiling averages signals across neoplastic cells, tumor-infiltrating lymphocytes, fibroblasts, and endothelial cells. Elevated expression of secreted factors like $DKK1$ or transporters like $RHCG$ may reflect high stromal content or metabolic stress in the microenvironment rather than intrinsic tumor cell genomics.
   * *Investigation:* Deconvolve bulk RNA-seq data using single-cell reference datasets (e.g., CIBERSORTx, Scaden) or validate targets using single-cell RNA-seq (scRNA-seq) and spatial transcriptomics.

4. **Omission of Critical Clinical Covariates:**
   * *Limitation:* Survival outcomes in LUAD are strongly confounded by tumor stage (Stage I vs. IV), patient age, smoking status, and oncogenic driver mutations ($EGFR$, $KRAS$, $ALK$, $TP53$). Univariable hazard ratios cannot establish whether transcripts like $KRT6A$ are independent prognostic markers or merely surrogates for advanced tumor stage.
   * *Investigation:* Fit multivariable Cox models incorporating AJCC stage, age, smoking history, and mutational status.

5. **Association vs. Causation Ambiguity:**
   * *Limitation:* Transcriptional upregulation of motility genes ($KRT6A$, $RHOF$) may represent a reactive, secondary manifestation of tumor hypoxia or stress, rather than a primary driver of disease progression.
   * *Investigation:* Conduct functional loss-of-function (CRISPR-Cas9 knockout) and gain-of-function experiments in orthotopic LUAD mouse models to evaluate causal impacts on metastasis and OS.
